false
0001527352
0001527352
2026-08-14
2026-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 14, 2026
NEXALIN TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-41507 |
|
27-5566468 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
| 1776 Yorktown Street, Suite 550, Houston, Texas |
|
77056 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone
number, including area code: (832) 260-0222
| Not Applicable |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading symbol |
|
Name of each exchange on which registered |
| Common Stock, par value $0.001 per share |
|
NXL |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
|
Item 3.01 |
Notice of Delisting or Failure
to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On
August 14, 2026, Nexalin Technology, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications
Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’
equity of $1,519,423 reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026, the Company no
longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market
under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter further notes that the Company
does not presently satisfy either of the alternative continued listing standards under Nasdaq Listing Rule 5550(b) (such non-compliance,
the “Stockholders’ Equity Deficiency”).
As
previously disclosed on July 24, 2026, the Company received a Staff Determination letter from Nasdaq (the “Delisting Notice”)
stating that the Company has not regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the
“Minimum Bid Price Requirement”) and is not eligible for an additional compliance period under Nasdaq Listing Rule 5810(c)(3)(A)
because the Company does not meet the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital
Market (the “Bid Price Deficiency”). The Company timely requested a hearing before a Nasdaq Hearing Panel (the “Panel”)
to appeal the Bid Price Deficiency, which is currently scheduled for September 1, 2026 (the “Hearing”).
The
Letter states that the Stockholders’ Equity Deficiency serves as an additional basis for delisting the Company’s securities
from Nasdaq, and that the Panel will consider the Stockholders’ Equity Deficiency, together with the Bid Price Deficiency, in rendering
its determination regarding the Company’s continued listing on The Nasdaq Capital Market. The Company intends to present its views
with respect to the Stockholders’ Equity Deficiency at the Hearing, together with its plan to evidence compliance with the Minimum
Bid Price Requirement and the Stockholders’ Equity Requirement.
There
can be no assurance that the Company will be successful in its appeal before the Panel, that the Panel will grant the Company any additional
period within which to regain compliance with the Stockholders’ Equity Requirement, the Minimum Bid Price Requirement, or any other
applicable Nasdaq continued listing standard, or that, if any such period is granted, the Company will be able to evidence compliance
with all applicable Nasdaq continued listing requirements within that period. The Panel has broad discretionary authority under Nasdaq
Listing Rules to delist the Company’s securities notwithstanding the Company’s compliance efforts, including based on concerns
regarding the Company’s reverse stock split history, financial condition, capital structure, capital-raising activities, or any
other factor the Panel deems appropriate. If the Panel determines to delist the Company’s securities, or if the Company is otherwise
unable to regain and maintain compliance with the applicable Nasdaq continued listing requirements, the Company’s common stock
would be subject to delisting from The Nasdaq Capital Market, which would have a material adverse effect on the liquidity and market
price of the Company’s common stock and on the Company’s ability to raise capital.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| Date: August 17, 2026 |
NEXALIN TECHNOLOGY, INC. |
| |
|
| |
/s/ Mark White |
| |
Mark White |
| |
Chief Executive Officer |